Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz.

about

The role of biosimilars in value-based oncology care Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar

P2860

Q58605622-A7026886-D4DC-498C-9CA9-9640B457409E Q58767839-AE592239-C84F-4316-965D-FC56D771495F

P2860

Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz.

Item

http://www.wikidata.org/entity/Q47965968

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Expanded access to cancer trea ...... th biosimilar filgrastim-sndz.

@en

Expanded access to cancer trea ...... th biosimilar filgrastim-sndz.

@nl

type

Item

label

Expanded access to cancer trea ...... th biosimilar filgrastim-sndz.

@en

Expanded access to cancer trea ...... th biosimilar filgrastim-sndz.

@nl

prefLabel

Expanded access to cancer trea ...... th biosimilar filgrastim-sndz.

@en

Expanded access to cancer trea ...... th biosimilar filgrastim-sndz.

@nl

P1476

Expanded access to cancer trea ...... th biosimilar filgrastim-sndz.

@en

P2093

Ali McBride

http://www.w3.org/2001/XMLSchema#string

Ivo Abraham

http://www.w3.org/2001/XMLSchema#string

Karen MacDonald

http://www.w3.org/2001/XMLSchema#string

Kim Campbell

http://www.w3.org/2001/XMLSchema#string

Mohan Bikkina

http://www.w3.org/2001/XMLSchema#string

Sanjeev Balu

http://www.w3.org/2001/XMLSchema#string

P2860

Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study.

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.

Potential cost savings from chemotherapy-induced febrile neutropenia with biosimilar filgrastim and expanded access to targeted antineoplastic treatment across the European Union G5 countries: a simulation study.

Colony-stimulating factors: clinical evidence for treatment and prophylaxis of chemotherapy-induced febrile neutropenia.

Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study).

Febrile neutropenia: a critical review of the initial management.

What do prescribers think of biosimilars?

Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors.

Clinical experience with Zarzio® in Europe: what have we learned?

P304

2285-2295

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON-2017-0374

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28870106

http://www.w3.org/2001/XMLSchema#string

Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz.

about

P2860

P2860

Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698